US Patent 11,969,469: Scope, Claims Architecture, and US Patent Landscape
US Patent 11,969,469 claims a specific aqueous pharmaceutical composition that combines: (i) Compound 1 (the active), (ii) a non-ionic, water-insoluble/immiscible ester co-surfactant that is a sorbitan ester of a C4-C20 carboxylic acid, (iii) a non-ionic, water-miscible/soluble surfactant, and (iv) an aqueous vehicle, with an explicit hydrolysis product impurity control and a defined weight ratio of the two surfactant/co-surfactant components.
The independent claim is claim 1. The dependent claims narrow surfactant chemistry and impose longer-term impurity control. Claims 7-8 add a more concrete formulation percent range for components and retain the hydrolysis constraint.
What does claim 1 actually cover? (core scope)
Claim 1 elements (composition + functional constraints)
Claim 1 requires all of the following:
-
Active
-
Co-surfactant (non-ionic ester, sorbitan ester, C4-C20)
- (b) a non-ionic water insoluble and/or immiscible ester co-surfactant
- is a sorbitan ester of a carboxylic acid
- the carboxylic acid contains 4-20 carbon atoms.
-
Primary surfactant (non-ionic, water miscible/soluble)
- (c) a water miscible and/or soluble non-ionic surfactant.
-
Aqueous vehicle
-
Hydrolysis-product impurity cap
- the composition contains less than 50 ppm of a hydrolysis product of Compound 1.
-
Surfactant ratio
- the weight ratio of components (b) to (c) is approximately 5:2.
Claim 1 claim-significance: enforceable boundaries
Claim 1 is not a broad “any surfactant improves stability” claim. It ties infringement to:
- Surfactant identity class (sorbitan ester co-surfactant of defined chain length range),
- Non-ionic and solubility/immiscibility properties (b is insoluble/immiscible; c is miscible/soluble),
- Aqueous formulation context,
- Quantitative impurity limit (<50 ppm hydrolysis product),
- Quantitative formulation ratio (b:c ≈ 5:2 by weight).
That structure creates a tight infringement funnel: an accused product must match all mandatory constraints, including impurity and ratio.
How do dependent claims narrow the invention? (claims 2-6)
Claim 2: longer-term stability threshold
- Requires claim 1’s entire scaffold.
- Adds an additional impurity limit:
- less than 30 ppm of the hydrolysis product after standing for at least 24 months.
Practical scope impact: This is a shelf-life/aging performance limitation. It narrows to compositions that maintain hydrolysis below a tighter threshold over time.
Claim 3: specifies the surfactant (c) subclass
Claim 3 depends on claim 1 and defines component (c):
- (c) is a polyoxyethylene derivative of a sorbitan ester of a carboxylic acid
- carboxylic acid contains 8-14 carbon atoms.
Impact: Claim 3 restricts the “water miscible/soluble non-ionic surfactant” to a polyoxyethylene-sorbitan ester family with a narrower carbon-number band (C8-C14).
Claim 4: specifies co-surfactant (b)
Laurate implies a C12 fatty chain, which falls within the claim 1 C4-C20 range.
Impact: This pins co-surfactant identity to a single commercial material (sorbitan laurate), removing variability in ester chain length.
Claim 5: specifies surfactant (c)
- The polyoxyethylene derivative of claim 3 is polysorbate 20.
Polysorbate 20 corresponds to a polyoxyethylene sorbitan ester with lauric acid components, matching the C8-C14 constraint.
Impact: This makes claim 5 a near-commercial-formulation level lock: it is not just “polyoxyethylene sorbitan ester”; it is polysorbate 20 specifically.
Claims 6, 8: what is the hydrolysis product defining hook?
Your excerpt shows claims 6 and 8 as incomplete in the text provided:
- Claim 6: “wherein the hydrolysis product of Compound 1 is: …” (missing the identity/specification)
- Claim 8: “wherein the hydrolysis product of Compound 1 is: …” (missing the identity/specification)
However, the claim architecture still matters: both claims are set up to define the hydrolysis product identity (likely a particular chemical species or structure), which can further narrow infringement compared with a generic “hydrolysis product” category.
Because the hydrolysis product identity is not included in the provided text, the enforceable scope cannot be fully resolved from the excerpt alone.
What do claims 7-8 add? (composition % scope)
Claim 7: percent-based embodiment
Claim 7 depends from claim 1 and states a formulation range by weight:
- (a) 15-35 weight percent Compound I
- (b) about 0.2-1 weight percent sorbitan laurate
- (c) about 0.1-0.3 weight percent polysorbate 20
- (d) an aqueous vehicle
- impurity constraint:
- less than 50 ppm hydrolysis product of Compound 1
- ratio constraint:
- (b) to (c) approximately 5 to 2 by weight
Claim 7 relative tightening
Claim 1 allows broad amounts of (a)-(d), with only impurity and ratio constraints. Claim 7 adds:
- explicit active loading window (15-35 wt%),
- explicit surfactant concentration windows for sorbitan laurate and polysorbate 20.
This is important for both infringement and design-around. If an accused product uses the same materials but shifts concentrations outside these windows, it may avoid claim 7 while still potentially implicating claim 1 (depending on whether claim 1 does not limit amounts beyond the ratio and ppm cap).
Claim 8
Claim 8 depends from claim 7 and again specifies:
- the hydrolysis product of Compound 1 is: … (missing identity/specification in your excerpt)
As with claim 6, without the missing portion the scope of the hydrolysis product definition cannot be fully pinned down.
Scope map: what is covered vs. what is not
Covered (must satisfy all)
A practicing formulation would fall within claim scope if it is:
- An aqueous pharmaceutical composition,
- Contains Compound 1 and the specific surfactant system:
- co-surfactant (b): sorbitan ester of C4-C20 carboxylic acid, non-ionic, water insoluble/immiscible,
- surfactant (c): non-ionic water miscible/soluble,
- Has hydrolysis product impurity below 50 ppm,
- Has (b):(c) by weight approximately 5:2.
And for the narrower dependent embodiments:
- <30 ppm after ≥24 months (claim 2),
- (c) polyoxyethylene derivative of sorbitan ester with C8-C14 chain lengths (claim 3),
- (b) sorbitan laurate (claim 4),
- (c) polysorbate 20 (claim 5),
- Specific hydrolysis product identity in claims 6 and 8 (not provided in excerpt),
- wt% composition windows in claim 7 (and again claim 8 for hydrolysis identity).
Not covered (typical ways products fall outside)
Based on the claim language, typical non-infringing variants would include:
- Using a different ester co-surfactant class (non-sorbitan ester or outside C4-C20 range),
- Replacing the non-ionic surfactant (c) with an ionic surfactant or a non-miscible surfactant (even if it works functionally),
- Missing the approximate 5:2 ratio (b:c) or failing the ppm hydrolysis cap,
- Operating above 50 ppm hydrolysis product,
- Failing the 24-month <30 ppm requirement for claim 2,
- Using different surfactants than sorbitan laurate + polysorbate 20 for claims 4-5,
- Formulating outside the 15-35 wt% active and/or the 0.2-1 wt% / 0.1-0.3 wt% surfactant windows for claim 7.
Enforcement posture: which claims are most potent?
Claim 1 is the broadest enforceable anchor
Claim 1 captures the core formulation concept and is the most likely to reach commercial compositions that implement similar surfactant chemistry and ratio but may not meet narrower identity and concentration subranges.
Claims 4-5 and 7 are the “commercial lock” layer
Claims 4 and 5 move from a generic sorbitan ester/polyoxyethylene sorbitan ester concept to:
- sorbitan laurate + polysorbate 20, which are common excipients.
Claim 7 then narrows to specific concentration ranges, which can be directly compared to product formulation labels, regulatory dossiers, or analytical characterization.
Claims 2, 6, 8 are performance/impurity specificity
- Claim 2 adds a time-dependent hydrolysis impurity threshold.
- Claims 6 and 8 likely define the exact hydrolysis product species, which can be a litigation fulcrum if accused products generate different degradation profiles.
US patent landscape: how to read the competitive space
What the claim set implies about prior art
The claim structure suggests the patent is positioned around:
- A sorbitan ester + polysorbate-type surfactant system,
- Hydrolysis degradation control of Compound 1 down to ppm level,
- Ratio optimization (approximately 5:2),
- Shelf-life performance.
This is the kind of formulation claim that often faces prior art from:
- Liquid/aqueous dosage form formulations containing polysorbates and sorbitan esters,
- Studies on hydrolysis of the active or similar chemotypes,
- Stability studies showing surfactant effects on degradation.
Landscape elements likely to exist in US
Within the US, you typically see these buckets around this type of formulation invention:
- Active compound patents (covering Compound 1 itself)
- Salt/hydrate polymorph patents (if relevant to Compound 1)
- Formulation patents (micelle, co-solvent, surfactant systems)
- Stability/impurity patents (hydrolysis suppression)
- Process patents (manufacturing that reduces degradation impurities)
The claim text you supplied is purely formulation-level, so its US landscape risk and opportunity are dominated by:
- Other formulation patents with similar surfactant/co-surfactant combinations,
- Other stability patents that claim impurity control by formulation changes,
- Any US patents tied to the same active (Compound 1) using sorbitan/polysorbate systems.
What can be concluded from the excerpt alone
A full “US patent landscape” for this specific patent number requires the patent’s publication history, family members, cited references, assignee, and the list of issued claims with dates. Your excerpt does not include any of those required identifiers, and no bibliographic data is provided.
Under the operating constraints, no incomplete landscape can be produced accurately without bibliographic and citation data for:
- US 11,969,469 itself (title, assignee, priority date, specification structure),
- its prosecution record (office actions and amendments),
- its cited prior art,
- and the existence of continuations/divisionals or related families.
Accordingly, only the claim-scope landscaping (category-level) can be stated from your text.
Key Takeaways
- Claim 1 defines a specific aqueous formulation architecture: Compound 1 + a non-ionic sorbitan ester co-surfactant (C4-C20) + a non-ionic water-miscible surfactant (c) + aqueous vehicle, with hydrolysis impurity <50 ppm and (b):(c) ≈ 5:2 by weight.
- Claims 4-5 lock the surfactant system to sorbitan laurate and polysorbate 20, narrowing the composition identity.
- Claim 2 adds a stringent aging constraint: <30 ppm after ≥24 months.
- Claim 7 adds explicit concentration windows (Compound 1 at 15-35 wt%, sorbitan laurate 0.2-1 wt%, polysorbate 20 0.1-0.3 wt%) while retaining the ppm cap and 5:2 ratio.
- Claims 6 and 8 likely specify the exact hydrolysis product identity, but the identity text is not provided in the excerpt, so the narrowest scope cannot be fully resolved from what is shown.
FAQs
1) Does claim 1 require a particular surfactant identity for component (c)?
It requires component (c) to be a non-ionic, water miscible/soluble surfactant. The identity is specified in dependent claims (e.g., claim 3 specifies a polyoxyethylene sorbitan ester, claim 5 specifies polysorbate 20).
2) What impurity limit must be met for claim 1?
The composition must contain less than 50 ppm of the hydrolysis product of Compound 1.
3) What is the role of the “approximately 5 to 2” ratio?
It constrains the weight ratio of the co-surfactant (b) to surfactant (c). That ratio is a mandatory quantitative limitation for both claim 1 and the embodiments of claim 7.
4) How does claim 2 narrow the invention relative to claim 1?
Claim 2 tightens the hydrolysis product specification to <30 ppm after at least 24 months.
5) Is claim 7 broader or narrower than claim 1?
Claim 7 is narrower, because it specifies formulation weight percent ranges for Compound 1, sorbitan laurate, and polysorbate 20, while maintaining the same core impurity and ratio constraints.
References
[1] Not provided in the prompt excerpt.
